8-K: Medinotec Inc. Announces 2024 Annual Meeting of Stockholders

Medinotec Inc. has scheduled its 2024 annual meeting of stockholders to be held virtually on February 19, 2025, with key proposals including the election of directors and the approval of the company's independent auditor.

Summary

• Medinotec Inc. will hold its 2024 Annual Meeting of Stockholders virtually on February 19, 2025, at 9:30 a.m. EST.
• The record date for determining stockholders eligible to vote at the meeting was December 5, 2024.
• Stockholders can vote by email, mail, or fax before the meeting, but will not be able to vote electronically during the meeting.
• The meeting will include proposals to elect five directors and approve Mercurius & Associates LLP as the company's independent auditor for the 2024 fiscal year.
• As of December 5, 2024, there were 11,733,750 shares of common stock outstanding and entitled to vote.
• The company's principal executive offices are located in North Riding, South Africa.
• The proxy statement and annual report for the year ended February 28, 2023, were distributed on or about January 20, 2025.

Sentiment

Score: 7

Explanation: The document is a routine corporate announcement, with no significant positive or negative surprises. The sentiment is neutral to slightly positive due to the standard corporate governance practices being followed.

Positives

• The company is providing multiple methods for shareholders to vote, including email, mail, and fax.
• The board is recommending a vote for all director nominees and the appointment of the independent auditor.
• The company has an Audit Committee with a financial expert on the committee.
• The company has adopted a Code of Business Conduct and Ethics.

Negatives

• Stockholders will not be able to vote electronically during the virtual annual meeting.
• The company has a related party loan with Minoan Medical Proprietary Limited, which is owned by the CEO.
• The company has related party sales to DISA Vascular Distribution, which was previously related to a director.

Risks

• The company has a related party loan that carries interest at the prevailing prime lending rate in South Africa, which could fluctuate.
• The company's sales are heavily reliant on a single distributor, DISA Life Sciences, which could pose a risk if the relationship changes.
• The company's related party transactions could raise concerns about conflicts of interest.
• The company is an emerging growth company and may face challenges in complying with new or revised financial accounting standards.

Future Outlook

The company has provided deadlines for stockholders to submit proposals for the 2025 annual meeting, indicating a continuation of the annual meeting process.

Management Comments

• The Board believes that Dr. Vizirgianakis has the experience, qualifications, attributes and skills necessary to serve on the Board because of the fact that he held similar positions for more than 10 years and his designation as a medical doctor, he is also a founding shareholder in the company and has a long-standing track record in the industry.
• The Board believes that Mr. van Niekerk has the experience, qualifications, attributes and skills necessary to serve on the Board because of the fact that he held similar positions for more than 10 years and his designation as a chartered accountant, he is also a founding shareholder in the company and has a long-standing track record in the industry.
• The Board believes Mr. Vizirgianakis industry knowledge, sales and marketing experience and his international business relationships qualify him to serve as a director.
• We have selected Mr. Spirakis to serve as an independent director because of his education, skills and experience in Biomedical Engineering, Manufacturing & Marketing / Selling of Medical Devices.

Industry Context

The announcement of the annual meeting is a standard corporate procedure for publicly traded companies. The virtual format of the meeting reflects a growing trend in corporate governance.

Comparison to Industry Standards

• The use of a virtual meeting format is becoming increasingly common among public companies, especially for annual shareholder meetings.
• The appointment of an independent auditor is a standard practice to ensure financial transparency and compliance.
• The disclosure of related party transactions is a requirement for public companies to maintain transparency and avoid conflicts of interest.
• The company's board composition, with a mix of executive and independent directors, is typical for a company of its size and stage.

Related Party Transactions

• The company leases commercial buildings from Minoan Capital Proprietary Limited, owned by the CEO.
• The company has a loan from Minoan Medical Proprietary Limited, also owned by the CEO.
• The company sells the majority of its stock to DISA Vascular Distribution, which was previously related to a director.

Stakeholder Impact

• Shareholders are required to vote on key proposals, including the election of directors and the appointment of the independent auditor.
• Employees are subject to the company's Code of Business Conduct and Ethics.
• The company's financial performance and governance practices impact its stakeholders, including customers and suppliers.

Next Steps

• Stockholders are to vote on the proposals by February 18, 2025.
• The company will hold its annual meeting on February 19, 2025.
• The company will continue to operate under the direction of the elected board of directors.

Key Dates

Keywords

Annual Meeting, Stockholders, Proxy Statement, Directors, Independent Auditor, Mercurius & Associates LLP, Corporate Governance, Related Party Transactions, Voting, Medinotec Inc.